Does the media refer more to PTCT or NKTR?

In the previous week, PTC Therapeutics had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 15 mentions for PTC Therapeutics and 10 mentions for Nektar Therapeutics. PTC Therapeutics' average media sentiment score of 0.46 beat Nektar Therapeutics' score of 0.45 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NKTR or ORKA?

In the previous week, Nektar Therapeutics had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 10 mentions for Nektar Therapeutics and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.79 beat Nektar Therapeutics' score of 0.45 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NKTR or MIRM?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Nektar Therapeutics and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.99 beat Nektar Therapeutics' score of 0.45 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRRK or NKTR?

In the previous week, Scholar Rock and Scholar Rock both had 10 articles in the media. Nektar Therapeutics' average media sentiment score of 0.45 beat Scholar Rock's score of 0.42 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nektar Therapeutics (NKTR) Competitors

$39.84 -1.33 (-3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$40.12 +0.28 (+0.70%)

As of 07:30 PM Eastern

Compare

NKTR vs. PTCT, ORKA, MIRM, COGT, and SRRK

Should you buy Nektar Therapeutics stock or one of its competitors? Nektar Therapeutics's main competitors and comparable companies include PTC Therapeutics (PTCT), Oruka Therapeutics (ORKA), Mirum Pharmaceuticals (MIRM), Cogent Biosciences (COGT), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nektar Therapeutics compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

75.9% of Nektar Therapeutics shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PTC Therapeutics has higher revenue and earnings than Nektar Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.12	$682.64M	-$0.58	N/A
Nektar Therapeutics	$55.23M	25.45	-$164.08M	-$6.70	N/A

In the previous week, PTC Therapeutics had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 15 mentions for PTC Therapeutics and 10 mentions for Nektar Therapeutics. PTC Therapeutics' average media sentiment score of 0.46 beat Nektar Therapeutics' score of 0.45 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

PTC Therapeutics has a net margin of -3.80% compared to Nektar Therapeutics' net margin of -287.84%. PTC Therapeutics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

PTC Therapeutics currently has a consensus price target of $98.25, indicating a potential upside of 51.85%. Nektar Therapeutics has a consensus price target of $138.50, indicating a potential upside of 236.41%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Nektar Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

PTC Therapeutics beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Oruka Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Nektar Therapeutics had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 10 mentions for Nektar Therapeutics and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.79 beat Nektar Therapeutics' score of 0.45 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nektar Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market.

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oruka Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Oruka Therapeutics' return on equity of -21.65% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Oruka Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	25.45	-$164.08M	-$6.70	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Nektar Therapeutics presently has a consensus price target of $138.50, suggesting a potential upside of 236.41%. Oruka Therapeutics has a consensus price target of $128.91, suggesting a potential upside of 57.00%. Given Nektar Therapeutics' higher probable upside, research analysts plainly believe Nektar Therapeutics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Oruka Therapeutics beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Mirum Pharmaceuticals?

Nektar Therapeutics (NASDAQ:NKTR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Nektar Therapeutics presently has a consensus price target of $138.50, indicating a potential upside of 236.41%. Mirum Pharmaceuticals has a consensus price target of $143.81, indicating a potential upside of 67.20%. Given Nektar Therapeutics' higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

75.9% of Nektar Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Nektar Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Nektar Therapeutics and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.99 beat Nektar Therapeutics' score of 0.45 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	25.45	-$164.08M	-$6.70	N/A
Mirum Pharmaceuticals	$521.31M	10.71	-$23.36M	-$14.55	N/A

Nektar Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -139.18% compared to Nektar Therapeutics' net margin of -287.84%. Mirum Pharmaceuticals' return on equity of -36.28% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Mirum Pharmaceuticals beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Cogent Biosciences?

Nektar Therapeutics (NASDAQ:NKTR) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

In the previous week, Nektar Therapeutics had 9 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Nektar Therapeutics and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Nektar Therapeutics' score of 0.45 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Nektar Therapeutics	Neutral
Cogent Biosciences	Very Positive

Nektar Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

75.9% of Nektar Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nektar Therapeutics presently has a consensus price target of $138.50, indicating a potential upside of 236.41%. Cogent Biosciences has a consensus price target of $51.56, indicating a potential upside of 66.31%. Given Nektar Therapeutics' higher possible upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Nektar Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	25.45	-$164.08M	-$6.70	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Cogent Biosciences has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summary

Nektar Therapeutics beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.

How does Nektar Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Scholar Rock has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Scholar Rock has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Nektar Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Nektar Therapeutics	$55.23M	25.45	-$164.08M	-$6.70	N/A

In the previous week, Scholar Rock and Scholar Rock both had 10 articles in the media. Nektar Therapeutics' average media sentiment score of 0.45 beat Scholar Rock's score of 0.42 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock presently has a consensus price target of $67.67, indicating a potential upside of 60.39%. Nektar Therapeutics has a consensus price target of $138.50, indicating a potential upside of 236.41%. Given Nektar Therapeutics' higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	2.94
Nektar Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Nektar Therapeutics beats Scholar Rock on 8 of the 15 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTR vs. The Competition

Export

Metric	Nektar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.41B	$3.92B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.53%	22.58%
P/E Ratio	-5.95	13.45	275.65	25.82
Price / Sales	24.92	1,250.23	622.54	95.26
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	9.03	17.35	10.85	6.10
Net Income	-$164.08M	-$22.69M	$3.50B	$380.59M
7 Day Performance	-5.64%	-3.32%	-2.14%	-2.34%
1 Month Performance	-42.89%	-9.38%	-4.88%	-4.22%
1 Year Performance	-26.68%	12.91%	6.00%	0.54%

Nektar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTR Nektar Therapeutics	3.0861 of 5 stars	$39.84 -3.2%	$130.67 +228.0%	-24.2%	$1.41B	$54.59M	N/A	63	Analyst Forecast
PTCT PTC Therapeutics	4.0511 of 5 stars	$63.23 -0.7%	$99.08 +56.7%	-2.3%	$5.28B	$1.01B	N/A	991	Analyst Downgrade Insider Trade
ORKA Oruka Therapeutics	2.864 of 5 stars	$79.50 -0.8%	$128.91 +62.1%	+235.3%	$5.26B	N/A	N/A	68
MIRM Mirum Pharmaceuticals	3.1474 of 5 stars	$80.64 +1.8%	$142.56 +76.8%	+18.3%	$5.24B	$521.31M	N/A	433	Trending News Analyst Forecast
COGT Cogent Biosciences	2.8402 of 5 stars	$30.14 -0.8%	$51.56 +71.1%	+90.5%	$5.23B	N/A	N/A	258	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nektar Therapeutics (NKTR) Competitors

NKTR vs. PTCT, ORKA, MIRM, COGT, and SRRK

How does Nektar Therapeutics compare to PTC Therapeutics?

Summary

How does Nektar Therapeutics compare to Oruka Therapeutics?

Summary

How does Nektar Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Nektar Therapeutics compare to Cogent Biosciences?

Summary

How does Nektar Therapeutics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nektar Therapeutics (NKTR) Competitors

NKTR vs. PTCT, ORKA, MIRM, COGT, and SRRK

How does Nektar Therapeutics compare to PTC Therapeutics?

Do insiders & institutionals have more ownership in PTCT or NKTR?

Which has better earnings & valuation, PTCT or NKTR?

Does the media refer more to PTCT or NKTR?

Which has more volatility & risk, PTCT or NKTR?

Is PTCT or NKTR more profitable?

Do analysts prefer PTCT or NKTR?

Summary

How does Nektar Therapeutics compare to Oruka Therapeutics?

Does the media prefer NKTR or ORKA?

Which has more volatility & risk, NKTR or ORKA?

Do institutionals & insiders hold more shares of NKTR or ORKA?

Is NKTR or ORKA more profitable?

Which has stronger valuation & earnings, NKTR or ORKA?

Do analysts rate NKTR or ORKA?

Summary

How does Nektar Therapeutics compare to Mirum Pharmaceuticals?

Do analysts recommend NKTR or MIRM?

Do insiders and institutionals believe in NKTR or MIRM?

Does the media prefer NKTR or MIRM?

Which has higher valuation & earnings, NKTR or MIRM?

Which has more volatility and risk, NKTR or MIRM?

Is NKTR or MIRM more profitable?

Summary

How does Nektar Therapeutics compare to Cogent Biosciences?

Does the media prefer NKTR or COGT?

Which has more risk & volatility, NKTR or COGT?

Do institutionals and insiders believe in NKTR or COGT?

Do analysts prefer NKTR or COGT?

Which has preferable valuation & earnings, NKTR or COGT?

Is NKTR or COGT more profitable?

Summary

How does Nektar Therapeutics compare to Scholar Rock?

Which has more risk and volatility, SRRK or NKTR?

Do institutionals & insiders believe in SRRK or NKTR?

Is SRRK or NKTR more profitable?

Which has stronger valuation & earnings, SRRK or NKTR?

Does the media favor SRRK or NKTR?

Do analysts rate SRRK or NKTR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools